Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma.

Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology.

J Neurooncol. 2019 Feb 6. doi: 10.1007/s11060-019-03116-z. [Epub ahead of print]

PMID:
30726533
2.

Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.

Vernieri C, Signorelli D, Galli G, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Broggini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto PA, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC.

Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30335-8. doi: 10.1016/j.cllc.2018.12.011. [Epub ahead of print]

PMID:
30617039
3.

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri V.

Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

4.

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.

Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, Torri V.

Adv Ther. 2019 Feb;36(2):381-406. doi: 10.1007/s12325-018-0844-4. Epub 2018 Dec 18.

PMID:
30565179
5.

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis.

Garassino MC, Kawaguchi T, Gregorc V, Rulli E, Ando M, Marsoni S, Isa SI, Novello S, Farina G, Barni S, Torri V, Cinquini M.

ESMO Open. 2018 Nov 1;3(6):e000327. doi: 10.1136/esmoopen-2018-000327. eCollection 2018. Review.

6.

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

Cazzaniga ME, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, Mavroudis D, Schem C, Steger G, Timotheadou E, Zaman K, Torri V; MACBETH Group.

Cancer Chemother Pharmacol. 2018 Nov 20. doi: 10.1007/s00280-018-3717-2. [Epub ahead of print]

PMID:
30460489
7.

Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM).

Dieci MV, Massari F, Giusti R, Inno A, Lombardi G, Noto L, Passaro A, Pietrantonio F, Spada F, Valente M, Di Maio M, Torri V.

ESMO Open. 2018 Oct 21;3(6):e000389. doi: 10.1136/esmoopen-2018-000389. eCollection 2018.

8.

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.

Rulli E, Ghilotti F, Biagioli E, Porcu L, Marabese M, D'Incalci M, Bellocco R, Torri V.

Br J Cancer. 2018 Dec;119(12):1456-1463. doi: 10.1038/s41416-018-0302-8. Epub 2018 Nov 13.

PMID:
30420618
9.

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).

Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators.

Cancer Treat Rev. 2018 Dec;71:76-87. doi: 10.1016/j.ctrv.2018.10.001. Epub 2018 Oct 5.

PMID:
30366202
10.

Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.

Garassino MC, Torri V, Colombo MP, Sica A.

Cancer Res. 2018 Oct 15;78(20):5729-5730. doi: 10.1158/0008-5472.CAN-18-2245.

PMID:
30322956
11.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.

PMID:
30206165
12.

Turn off pain evaluates the quality of pain care provided for paediatric inpatients.

Benini F, Lazzarin P, Borrometi F, Jankovic M, Torri V, Giacomelli L, Gentili M.

Acta Paediatr. 2019 Jan;108(1):16-18. doi: 10.1111/apa.14562. Epub 2018 Sep 21. No abstract available.

PMID:
30168610
13.

The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results.

Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, Katsanos A, Longo A, Uva MG, Oddone F, Torri V, Weinreb RN.

J Glaucoma. 2018 Oct;27(10):856-863. doi: 10.1097/IJG.0000000000001038.

PMID:
30095601
14.

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.

Gadducci A, Grosso F, Scambia G, Raspagliesi F, Colombo N, Grignani G, Casali P, Sanfilippo R, Buonadonna A, Santoro A, Bruzzone M, Artioli G, Lorusso D, Biagioli E, Fossati R, Galli F, Negri E, Rulli E, Torri V, D'Incalci M.

Br J Cancer. 2018 Aug;119(5):565-571. doi: 10.1038/s41416-018-0190-y. Epub 2018 Jul 30.

PMID:
30057406
15.

RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M, Marabese M, Broggini M, Marino M, Trama A, Rulli E, Hollander L, Pruneri G, Torri V, Garassino MC.

Clin Lung Cancer. 2018 Sep;19(5):e811-e814. doi: 10.1016/j.cllc.2018.06.005. Epub 2018 Jul 3.

PMID:
30033090
16.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Aug;10(8). pii: e8741. doi: 10.15252/emmm.201708741.

17.

Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients.

Rigamonti A, Imbesi F, Silvani A, Gaviani P, Agostoni E, Porcu L, De Simone I, Torri V, Salmaggi A.

J Neurol Sci. 2018 Jul 15;390:14-19. doi: 10.1016/j.jns.2018.04.004. Epub 2018 Apr 5.

PMID:
29801876
18.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
19.

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.

Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4.

PMID:
29625841
20.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T.

N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.

21.

Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.

Anzalone N, Castellano A, Cadioli M, Conte GM, Cuccarini V, Bizzi A, Grimaldi M, Costa A, Grillea G, Vitali P, Aquino D, Terreni MR, Torri V, Erickson BJ, Caulo M.

Radiology. 2018 Jun;287(3):933-943. doi: 10.1148/radiol.2017170362. Epub 2018 Jan 22.

PMID:
29361245
22.

Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study.

Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, Katsanos A, Oddone F, Torri V, Weinreb RN; Italian Study Group on QoL in Glaucoma.

Sci Rep. 2018 Jan 12;8(1):619. doi: 10.1038/s41598-017-19113-z.

23.

The prognostic role of tumor size in early breast cancer in the era of molecular biology.

Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, Cordovana A, Farina G, Bramati A, Piva S, Dazzani MC, Paternò E, La Verde NM.

PLoS One. 2017 Dec 6;12(12):e0189127. doi: 10.1371/journal.pone.0189127. eCollection 2017.

24.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.

PMID:
29054815
25.

The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results.

Quaranta L, Biagioli E, Riva I, Galli F, Poli D, Rulli E, Katsanos A, Longo A, Uva MG, Torri V, Weinreb RN.

J Glaucoma. 2017 Nov;26(11):987-994. doi: 10.1097/IJG.0000000000000773.

PMID:
28957960
26.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

27.

A MALT lymphoma prognostic index.

Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E.

Blood. 2017 Sep 21;130(12):1409-1417. doi: 10.1182/blood-2017-03-771915. Epub 2017 Jul 18.

28.

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.

Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V; on behalf of; EVA Study Group.

Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

PMID:
28711793
29.

Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy.

Mattavelli I, Patuzzo R, Torri V, Gallino G, Maurichi A, Lamera M, Valeri B, Bolzonaro E, Barbieri C, Tolomio E, Moglia D, Nespoli AM, Galeone C, Saw R, Santinami M.

Eur J Surg Oncol. 2017 Aug;43(8):1536-1541. doi: 10.1016/j.ejso.2017.05.013. Epub 2017 May 25.

PMID:
28583789
30.

Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials.

Bernardo A, Palumbo R, Pedersini R, Rota Caremoli E, Gambaro AR, Ferzi A, Riva F, Grasso D, Danova M, Tarenzi E, Torri V, Cazzaniga ME.

Clin Breast Cancer. 2017 Oct;17(6):433-440. doi: 10.1016/j.clbc.2017.03.004. Epub 2017 Mar 9.

PMID:
28366406
31.

Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis.

Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Contaldo G, Stella A, Pozzi C, Ondei P, Minoretti C, Gallieni M, Pontoriero G, Conte F, Torri V, Bertoli S, Vincenti A.

Blood Purif. 2017;44(1):77-88. doi: 10.1159/000464347. Epub 2017 Apr 1.

32.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29.

PMID:
28355112
33.

Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM).

Di Maio M, Bruzzi P, Perrone F, Torri V, Montemurro F, Tiseo M, Vasile E.

ESMO Open. 2016 Dec 12;1(6):e000109. doi: 10.1136/esmoopen-2016-000109. eCollection 2016. Review.

34.

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.

Ann Oncol. 2017 Jun 1;28(6):1230-1242. doi: 10.1093/annonc/mdx054. Review.

35.

Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials.

Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):313-322. doi: 10.1016/j.ijrobp.2016.10.030. Epub 2016 Oct 24. Review.

PMID:
28068239
36.

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G.

Gastric Cancer. 2017 Sep;20(5):825-833. doi: 10.1007/s10120-016-0681-6. Epub 2016 Dec 27.

PMID:
28028664
37.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

38.

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.

PMID:
27647223
39.

Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Pinto C, Antonuzzo L, Porcu L, Aprile G, Maiello E, Masi G, Petrelli F, Scartozzi M, Torri V, Barni S.

Clin Colorectal Cancer. 2017 Jun;16(2):e61-e72. doi: 10.1016/j.clcc.2016.08.006. Epub 2016 Aug 31. Review.

40.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M.

Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.

41.

Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline Characteristics.

Quaranta L, Biagioli E, Galli F, Poli D, Rulli E, Riva I, Hollander L, Katsanos A, Longo A, Uva MG, Torri V, Weinreb RN.

Adv Ther. 2016 Aug;33(8):1305-15. doi: 10.1007/s12325-016-0358-x. Epub 2016 Jun 16.

42.

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.

Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, Ceresoli G, Magnani C, Silvestri S, Veltri A, Papotti M, Rossi G, Ricardi U, Trodella L, Rea F, Facciolo F, Granieri A, Zagonel V, Scagliotti G.

Crit Rev Oncol Hematol. 2016 Aug;104:9-20. doi: 10.1016/j.critrevonc.2016.05.004. Epub 2016 May 13.

PMID:
27286698
43.

Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologist.

Corli O, Martoni AA, Porcu L, Roberto A, Pinto C, Torri V, Guglieri I, Zagonel V; EPIDEMIOLOGY STUDY OF PAIN IN ONCOLOGY (ESOPO) GROUP.

Eur J Intern Med. 2016 Sep;33:e18-9. doi: 10.1016/j.ejim.2016.04.019. Epub 2016 May 5. No abstract available.

PMID:
27155804
44.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).

Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.

PMID:
27132696
45.

Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer.

Di Cosimo S, Bregni G, Daidone MG, Cinquini M, de Braud F, Torri V.

Breast. 2016 Jun;27:187-8. doi: 10.1016/j.breast.2016.02.002. Epub 2016 Apr 23. No abstract available.

PMID:
27118634
46.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.

Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420.

47.

In memoriam: Dr. Irene Claudia Floriani (1964-2016).

Torri V, Hollander L, Mazziotti G.

Endocrine. 2016 Apr;52(1):178-9. doi: 10.1007/s12020-016-0891-z. Epub 2016 Feb 29. No abstract available.

PMID:
26924151
48.

Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Hines et al.

Rosati G, Mosconi P, Torri V, Apolone G, Johnson FE, Fossati R.

Ann Oncol. 2016 Jun;27(6):1171. doi: 10.1093/annonc/mdw076. Epub 2016 Feb 23. No abstract available.

PMID:
26912556
49.

A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma.

Rosati G, Ambrosini G, Barni S, Andreoni B, Corradini G, Luchena G, Daniele B, Gaion F, Oliverio G, Duro M, Martignoni G, Pinna N, Sozzi P, Pancera G, Solina G, Pavia G, Pignata S, Johnson F, Labianca R, Apolone G, Zaniboni A, Monteforte M, Negri E, Torri V, Mosconi P, Fossati R; GILDA working group.

Ann Oncol. 2016 Feb;27(2):274-80. doi: 10.1093/annonc/mdv541. Epub 2015 Nov 16.

PMID:
26578734
50.

ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease.

Prencipe N, Floriani I, Guaraldi F, Di Giacomo SV, Cannavo S, Arnaldi G, Berton A, Torri V, Spinello M, Arvat E, Ghigo E, Grottoli S.

Clin Endocrinol (Oxf). 2016 Mar;84(3):380-5. doi: 10.1111/cen.12959. Epub 2015 Oct 21.

PMID:
26433136

Supplemental Content

Support Center